Coya Therapeutics Inc (COYA) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access COYA quarterly Cash Flow →
Reviewing cash flow data across recent quarters allows users to assess how Coya Therapeutics Inc adapts its cash strategy across cycles.
Annual Report, GAAP in USD millions
ITEM
(Dec 31 2025)
12 Months
(Dec 31 2024) (Dec 31 2023) (Dec 31 2022)
Operating Activities
Income-21.23
Depreciation & amortization0.03
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.45
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
Research and Development in Process0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation4.29
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
In Process Research And Development2.29
Increase Decrease In Collaboration Receivable-
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable-0.53
Increase (Decrease) in Accrued Liabilities1.10
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets2.85
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-10.74
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Payments To Acquire Fixed Assets-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire in Process Research and Development-1.16
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-1.16
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock20.39
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Payment Of Deferred Financing Costs Related To Initial Public Offering-
Proceeds From Founders For Subscription Receivable-
Proceed From Sale Of Common Stock From Private Placement Net Of Offering Cost-
Proceeds From Subscription Receivable-
Payment Of Financing Costs Related To Private Placement-
Proceeds From Sale Of Common Stock From Private Placement Net Of Offering Cost-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities20.39
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-10.74
Total Cash Flow8.48
4 historic quarters locked

Sign in to unlock the full Coya Therapeutics Inc cash flow history.

About Coya Therapeutics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-107281

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document





                    
Get the full CSIMarket dataset: Subscribe API License